Chronic idiopathic constipation.
May be taken with or without food.
Oral Chronic idiopathic constipation Adult: 2 mg once daily. Elderly: Initially, 1 mg once daily, may increase to 2 mg once daily if necessary. Hepatic Impairment Severe (Child-Pugh Class C): Initially, 1 mg once daily, may increase to 2 mg once daily if necessary.
Severe (GFR <30 mL/min/1.73 m2): 1 mg once daily. Patient on dialysis: Contraindicated.
Intestinal obstruction or perforation, obstructive ileus, active severe inflammatory bowel conditions (e.g. Crohn’s disease, toxic megacolon/megarectum, and ulcerative colitis). Renal impairment requiring dialysis. Pregnancy and lactation.
Prucalopride is a selective 5-HT4 receptor agonist w/ prokinetic effect. It stimulates peristaltic reflex, intestinal secretions, and GI motility.
Patient w/ history of arrhythmias or ischaemic CV disease, severe and unstable concomitant disease (e.g. cancer, AIDS, neurological or psychiatric, pulmonary, IDDM or other endocrine disroders). Severe hepatic (Child-Pugh Class C) and renal (GFR <30 mL/min/1.73 m2) impairment. Elderly. This drug may cause dizziness and fatigue, if affected, do not drive or operate machinery. Monitoring Parameters: Monitor bowel movement frequency.
Nervous: Headache, dizziness, fatigue, malaise, tremors. CV: Palpitations. GI: Nausea, abdominal pain and distention, diarrhoea, vomiting, flatulence, dyspepsia, anorexia, rectal bleeding, gastroenteritis. Genitourinary: Polyuria, pollakiuria. Musculoskeletal: Muscle spasm. Others: Fever.
May decrease serum concentration of contraceptives (i.e. oestrogens, progestins). May enhance adverse effect of levosulpiride. Increased serum concentration w/ P-glycoprotein/ABCB1 inhibitors. Reduced effect w/ atropine-like substance.